Heterobicyclic metalloprotease inhibitors

US7713966B2 · kind B2 · utility

Assignee

• Alantos Pharmaceuticals Holding, Inc. · US

Inventors

• Christian Gege · Ehingen (Donau), DE
• Matthias Schneider · Dossenheim, DE
• Carine Chevrier · Munich, DE
• Hongbo Deng · Southborough, US
• Irving Sucholeiki · Watertown, US
• Brian Gallagher · Merrimac, US
• Michael Bosies · Weinheim, DE
• Christoph Steeneck · Dossenheim, DE
• Xinyuan Wu · Newton, US
• Matthias Hochgürtel · Schriesheim, DE
• Bert Nolte · Aachen, DE
• Arthur G. Taveras · Rockaway, US

Key dates

• Filing date: Nov 20, 2007
• Grant date: May 11, 2010
• Expiry date: Nov 20, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.